Newsweek interviewed a remarkable constellation of experts through its AI Impact series. Here are 6 lessons you can actually ...

Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic ...

Can MeitY's consent management guidelines offer solutions for consent fatigue and children's data? Read on to know what ...

Leading experts from top global institutions reveal how innovative image-based tools and clinical reasoning strategies ...

Sensitivity indicates how likely a test is to detect a condition when it is actually present in a patient. When a test’s sensitivity is high, it is less likely to give a false negative.In a test with ...

The U.S. Food and Drug Administration (USFDA) has cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer's disease.The Lumipulse G pTau217/ß-Amyloid ...

MALVERN, Pa., & TOKYO, May 17, 2025--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1 ...

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With ...

MALVERN, Pa., & TOKYO--(BUSINESS WIRE)-- Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse G pTau 217/β-Amyloid 1-42 ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to the first blood test to aid in diagnosing Alzheimer’s disease (AD). The Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma ...

Despite spending 16 nights in a jail cell, I never lost hope in the inevitability of justice and the principles of democracy. I wanted to become a citizen of this country because I believe in the ...

FDA approves first at-home, over-the-counter test for STIs. But it's not for everyone. The at-home, over-the-counter test screens for chlamydia, gonorrhea and trichomoniasis.